Compound medicinal composition for treating acute lymphocytic leukemia

A technology of lymphoid leukemia and composition, applied in the direction of drug combination, active ingredient of heterocyclic compound, anti-tumor drug, etc.

Active Publication Date: 2011-04-27
CHINA PHARM UNIV
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there are few reports on the use of this compound in anti-leukemia treatment research. Our research group has previously confirmed that 6S has a good anti-acute leukemia effect on human leukemia U937, Jurkat and HL-60 cell lines [6-S treatment of cervical cancer The medicinal use of cancer, leukemia and breast cancer, Chinese Invention Patent Publication No.: 101721397A]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicinal composition for treating acute lymphocytic leukemia
  • Compound medicinal composition for treating acute lymphocytic leukemia
  • Compound medicinal composition for treating acute lymphocytic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Anti-leukemic effect of 6-shogaol in vitro

[0019] Take the cells in the logarithmic growth phase and inoculate 3×10 4 Cells / well were placed on a 96-well plate, and after 4-6 hours of growth, they were administered in groups as follows: Tumor cells were divided into groups without treatment and groups with treatment (concentration: 2.5-30 μM), with 5 or 6 tumor cells in each group. Duplicate wells, in which Salubrinal was pretreated for 1-2 hours, then added 6-shogaol and incubated for 6, 12 and 24 hours, added 20 μl MTT (tetrazolium salt) containing 0.5 mg / ml and incubated for 4 hours, added 100 μl triplex (10% SDS, 5% isobutanol, 0.012mol / L HCL) overnight (or detect after 4 hours in DMSO); place on a micro-oscillator to shake for 10 minutes, and then place on a microplate reader to detect the OD value at 570nm. Each experiment was repeated 3 times. see results figure 1 .

[0020] Table 16S is used alone or in combination with 5 μ M Sal to act on the IC of Jurkat...

Embodiment 2

[0025] Effects of different concentrations of Salubrinal alone or in combination with 15 μM 6-shogaol on the viability of Jurkat cells

[0026] Take the Jurkat cells in the logarithmic growth phase, treat them according to the method in Example 1, and use different concentrations of Salubrinal (5, 10, 20, 40, 80 μM) alone or in combination with 15 μM 6-S to act on the cells for 12 and 24 hours (molar ratio 1:3-6:1), MTT evaluates cell viability. see results figure 2 .

[0027] from figure 2 We can obtain that Salubrinal at a concentration below 80 μM has no cytotoxic effect on leukemia Jurkat cells. When combined with 15 μM 6-shogaol, it has a significant increase in cytotoxicity and inhibits cell growth. At the same time, we found no concentration-dependent effect of Salubrinal combined with 15 μM 6-shogaol. This suggests that we use low concentration of Salubrinal can synergistically inhibit the proliferation of leukemia cells with 6-shogaol.

Embodiment 3

[0029] Effects of 5 μM Salubrinal and different concentrations of 6-S on the viability of leukemia Jurkat cells

[0030] According to the research basis of Example 3, we used 5 μM Salubrinal alone and or different concentrations (2.5, 5, 10, 15 μM) of 6S combinations (molar ratio of 2:1-1:3) to act on 3, 6, 12 and After 24 hours, the leukemia Jurkat cell viability was analyzed, and the MTT in Example 1 was also used to detect the change of cell viability. The results are shown in image 3 .

[0031] from image 3 The results showed that the 5μM Salubrinal and different concentrations (2.5, 5, 10, 15μM) of 6S composition were more significant than the cell viability reduction of 6S alone, suggesting that 5μM Salubrinal was different from the different concentrations (2.5, 5, 10, 15μM ) of 6S has obvious synergistic effect.

[0032] In order to further confirm the above-mentioned anti-proliferation effect, we detected the apoptosis rate of Jurkat cells treated with 5 μM Salub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of natural medicaments, and discloses a compound medicinal composition for treating acute lymphocytic leukemia. The compound medicinal composition is characterized by containing 6-shogaol and Salubrinal. The composition of the 6-shogaol and the Salubrinal can generate biological effect of high-dose 6-shogaol at low-dose compatibility so as to greatly reduce the clinical use dose of the 6-shogaol, reduce potential toxic or side effect, improve safety indexes of clinical treatment and obtain good clinical medicament development prospect.

Description

technical field [0001] The invention relates to the field of natural medicines, and discloses a compound pharmaceutical composition containing 6-shogaol and Salubrinal and its medical application. Background technique [0002] Acute lymphoblastic leukemia (ALL) is a serious and life-threatening progressive malignant disease. ALL accounts for 80% of acute leukemia in children, and the peak incidence is between 3 and 7 years old. ALL can also occur in adults and accounts for 20% of all adult leukemias. In recent years, the disease-free survival rate (DFS) of children with ALL has reached more than 80% [Reducing the dose of anthracycline antibiotics and head radiotherapy can improve the treatment of acute lymphoblastic leukemia in children: clinical reports from acute lymphoblastic leukemia-BFM 90 (Germany- Australia-Swiss Acute Lymphoblastic Leukemia Research Joint Center). Blood, 2000, 95 (11): 3310-3322. St Jude Children's Hospital's long-term treatment results for 11, 12 a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/47A61K31/12A61P35/02
CPCA61K31/12A61K31/4706A61P35/02A61K2300/00
Inventor 李萍彭咏波齐炼文闻晓东周萍高宁陈君
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap